
LambdaGen Therapeutics
LambdaGen Therapeutics envisions developing next-generation stem cells-derived off-the-shelf and affordable immune cell-based immunotherapies. We are leveraging the versatile potential of our proprietary genome engineering tool called LIGIT (Lambda (λ)-Integrase Genome Insertion Tool) that allows specific insertion of large multi-gene cassettes or DNA fragments at safe harbor sites in the human genome, uniquely positioning us to develop innovative gene therapies and cancer immunotherapies.
Specifically, one of the LambdaGen’s strategies include integrating multi-functional units as anti-tumor circuits into the genome of iPSCs by seamless transgenesis to generate different immune cells (NK, macrophages etc) with enhanced anti-tumor characteristics against different cancer types. Our approach would resolve several outstanding limitations with current practices and lead to desirable outcomes in improving tumor specificity, avoiding tumor immune escape; endowing sustained proliferative signals with unlimited safe sources of multifunctional-CAR-NK cells via iPSCs.
Lambdagen strategically collaborates with Plasticell, United Kingdom to access their proprietary combinatorial technology (Combicult) for developing feeder-free and efficient differentiation protocols for NK cells and other iPSC-immune cell derivatives.
We are looking for academic and clinical collaborators and partners in Singapore in stem cell based cancer immunotherapy space to advance our product pipelines.